ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary

Neuroendocrinology

Volumn 95, Issue 2, 2012, Pages 157-176

  Pavel, Marianne ^a   Baudin, Eric ^b   Couvelard, Anne ^c   Krenning, Eric ^d   Öberg, Kjell ^e   Steinmüller, Thomas ^f   Anlauf, Martin ^g   Wiedenmann, Bertram ^a   Salazar, Ramon ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BEAUJON HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f DRK KLINIKEN BERLIN WESTEND   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; ANTIEMETIC AGENT; CAPECITABINE; CISPLATIN; DIAZOXIDE; DOXORUBICIN; EDOTREOTIDE; EDOTREOTIDE YTTRIUM 90; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; IRINOTECAN; LUTETIUM 177; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANEMIA; ARTIFICIAL EMBOLISM; ASTHENIA; CANCER FATIGUE; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURGERY; CARCINOID SYNDROME; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; DIARRHEA; DISTANT METASTASIS; FOLLOW UP; FOREGUT NEOPLASM; GASTROINTESTINAL TUMOR; HINDGUT NEOPLASM; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULINOMA; LASER THERMOTHERAPY; LIVER METASTASIS; LIVER TRANSPLANTATION; MIDGUT NEOPLASM; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIOFREQUENCY ABLATION; RASH; REVIEW; STOMATITIS; TREATMENT RESPONSE;

HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS;

EID: 84857838286     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000335597     Document Type: Review

References (143)

1. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al: Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40: 30-40.
2. Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al: One hundred years after 'carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
4. Rindi G, Arnold R, Bosman FT, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, Carneiro F, Hruban H, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, IARC, 2010, pp 13-14.
5. García-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-1803.
6. Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B: Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097.
7. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, et al; FFCDANGH-GERCOR. Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 2009; 89: 217-222.
8. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
9. Strosberg J, Gardner N, Kvols L: Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the midgut. Neuroendocrinology 2009; 89: 471-476.
10. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al: Midgut neuroendocrine tumours with liver metastases: Results of the UKINETS study. Endocr Relat Cancer 2009; 16: 885-894.
11. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, Koch M, et al: Neuroendocrine tumors of midgut and hindgut origin: Tumor node metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341.
12. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908. (Pubitemid 351627305)
13. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM: Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19: 1727-1733.
14. Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: A report from the PROMID Study Group. J Clin Oncol 2009; 28: 4656-4663.
15. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al: Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.
16. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, et al: Ki67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer 2010; 18: 51-59.
17. Townsend A, Price T, Yeend S, Pittman K, Patterson K, Luke C: Metastatic carcinoid tumor: Changing patterns of care over two decades. J Clin Gastroenterol 2010; 44: 195-199.
18. Que FG, Nagorney DM, Batts KP, et al: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36-42.
19. Touzios JG, Kiely JM, Pitt SC, et al: Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg 2005; 241: 776-783.
20. Akerström G, Hellman P: Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109. (Pubitemid 46421901)
21. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, et al: Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma, Endocr Relat Cancer 2009; 16: 585-597.
22. Bernheim AM, Connolly HM, Hobday TJ, Abel MD, Pellikka PA: Carcinoid heart disease. Prog Cardiovasc Dis 2007; 49: 439-451. (Pubitemid 46693943)
23. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL: Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: A critical appraisal of 48 cases. Ann Surg 2010; 251: 910-916.
24. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao J: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22: 4762-4771.
25. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al: Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-1092. (Pubitemid 41815799)
26. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, et al: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827.
27. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8: 685-690. (Pubitemid 27372168)
28. Ardill JE: Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann Clin Biochem 2008; 45: 539-559.
29. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A -biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-2443.
30. Jain R, Fischer S, Serra S, Chetty R: The use of cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol 2010; 18: 9-15.
31. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al: Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28: 245-255.
32. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al: Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62. (Pubitemid 350308294)
33. Kos-Kudla B, O'Toole D, Falconi M, Gross D, Klöppel G, Sundin A, et al: ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 2010; 91: 341-350.
34. Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmüller T, et al: ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology 2010; 91: 326-332.
35. Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, et al: ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 2010; 91: 333-340.
36. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al: European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401. (Pubitemid 44451313)
37. Klöppel G, Couvelard A, Perren A, et al: Guidelines for the standards of care in neuroendocrine tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009; 90: 162-166.
38. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, et al: European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182.
39. De Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al: European Neuroendocrine Tumor Society: Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 2006; 84: 183-188.
40. Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P, et al: Hereditary neuroendocrine tumors of the gastroenteropancreatic system. Virchows Arch 2007; 451(suppl 1):S29-S38. (Pubitemid 47283381)
41. Srivastava A, Hornick JL: Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009; 33: 626-632.
42. Lin X, Saad RS, Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y: Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007; 15: 407-414. (Pubitemid 350307846)
43. Schmitt AM, Riniker F, Anlauf M, et al: Islet-1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008; 32: 420-425. (Pubitemid 351398934)
44. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, Mariani G: Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008; 52: 323-333.
45. Patel CN, Chowdhury FU, Scarsbrook AF: Clinical utility of hybrid SPECT-CT in endocrine neoplasia. AJR Am J Roentgenol 2008; 190: 815-824. (Pubitemid 351304530)
46. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP: Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68 Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010; 37: 67-77.
47. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al: Bone metastases in patients with neuroendocrine tumor: 68 Ga-DOTA-Tyr 3 -octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50: 1214-1221.
48. Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P: Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: An endoscopic ultrasound imaging study. Endocr Relat Cancer 2006; 13: 1195-1202. (Pubitemid 46212573)
49. Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al: 68Ga-DOTANOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (Octreoscan® ). Mol Imaging Biol 2011; 13: 583-593.
50. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: Spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52: 697-704.
51. 68Ga-DOTA-Tyr 3 -octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518. (Pubitemid 47571404)
52. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Bergstrom M, Eriksson B: Whole-body 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400. (Pubitemid 41014303)
53. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG: Improved staging of patients with carcinoid and islet cell tumors with 18 F-dihydroxy-phenyl-alanine and 11 C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26: 1489-1495.
54. 18F- fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978-985.
55. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK: Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145: 276-280.
56. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference Participants: European Neuroendocrine Tumor Society: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Radiological examinations. Neuroendocrinology 2009; 90: 167-183.
57. Eriksson B, Klöppel G, Krenning E Ahlman H, Plöckinger U, Wiedenmann B, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors -well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19. (Pubitemid 350308290)
58. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder W, et al: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195. (Pubitemid 46361053)
59. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37. (Pubitemid 36759176)
60. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al: Liver resection (and associated extrahepatic resections) for metastatic well differentiated endocrine tumors: A 15-year single-center prospective study. Surgery 2003; 133: 375-382. (Pubitemid 36515325)
61. Chamberlain R, Canes D, Brown K, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445. (Pubitemid 30181109)
62. Chen H, Hardacre J, Uzar A, Cameron J, Choti M: Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998; 187: 88-92.
63. Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J: Surgical treatment of gastric, enteric, and pancreatic endocrine tumors. Part 2. Treatment of hepatic metastases. J Chir (Paris) 2005; 142: 208-219. (Pubitemid 41323543)
64. Sarmiento J, Que F: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003; 12: 231-242. (Pubitemid 36210867)
65. Ahlman H, Wangberg B, Jansson S, Friman S, Olausson M, Tylen U, Nilsson O: Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(suppl 1):59-68. (Pubitemid 30665941)
66. Reddy SK, Clary BM: Neuroendocrine liver metastases. Surg Clin North Am 2010; 90: 853-861.
67. Jaeck D, Oussoultzoglou E, Bachellier P: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: Safe hepatic surgery. World J Surg 2001; 25: 689-692. (Pubitemid 32531909)
68. Yigitler C, Farges O, Kianmanesh R, Regimbeau J, Abdalla E, Belghiti J: The small remnant liver after major liver resection: How common and how relevant? Liver Transpl 2003; 9:S18-S25. (Pubitemid 37098861)
69. Hemming A, Reed A, Howard R, Fujita S, Hochwald S, Caridi J, Hawkins I, Vauthey J: Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237: 686-691.
70. Öberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973. (Pubitemid 39004355)
71. Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP: Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15: 5867-5870.
72. Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Lévy P, Belghiti J, Ruszniewski P: Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 2009; 145: 69-75.
73. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M: Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8: 208-212. (Pubitemid 38224261)
74. Pfitzmann R, Benscheidt B, Langrehr J, Schumacher G, Neuhaus R, Neuhaus P: Trends and experiences in liver retransplantation over 15 years. Liver Transpl 2007; 13: 248-257. (Pubitemid 46351651)
75. Pascher A, Klupp J, Neuhaus P: Transplantation in the management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 637-648. (Pubitemid 41447723)
76. Ahlman H, Friman S, Cahlin C, et al: Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann NY Acad Sci 2004; 1014: 265-269. (Pubitemid 38594814)
77. Mazzaferro V, Pulvirenti A, Coppa J: Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? J Hepatol 2007; 47: 460-466. (Pubitemid 47331755)
78. Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al: Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: An 85-case French multicentric report. Am J Transplant 2008; 8: 1205-1213. (Pubitemid 351763685)
79. Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma: An analysis of 103 patients. Transplantation 1998; 66: 1307-1312. (Pubitemid 28551010)
80. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, Ahlman H: Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002; 26: 998-1004. (Pubitemid 36920299)
81. Gurusamy KS, Pamecha V, Sharma D, Davidson BR: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastroenteropancreatic neuroendocrine tumours. Cochrane Database Syst Rev 2009;21(1):CD007118.
82. Siperstein A, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001; 25: 693-696. (Pubitemid 32531910)
83. Berber E, Flesher N, Siperstein A: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26: 985-990. (Pubitemid 36920297)
84. Pawlik T, Izzo F, Cohen D, Morris J, Curley M: Combined resection and radiofrequency ablation for advanced hepatic malignancies: Results in 172 patients. Ann Surg Oncol 2003; 10: 1059-1069. (Pubitemid 40486830)
85. Evard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V: Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol 2004; 30: 399-406. (Pubitemid 38528924)
86. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al: Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008; 32: 930-938.
87. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19. (Pubitemid 47042092)
88. Elias D, Baton O, Sideris L, Boige V, Malka D, Liberale G, Pocard M, Lasser P: Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005; 90: 36-42. (Pubitemid 40446473)
89. Gillams A. Liver ablation therapy. Br J Radiol 2004; 77: 713-723. (Pubitemid 39386917)
90. Veenendaal L, de Jager A, Stapper G, Borel Rinkes I, van Hillegersberg R: Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg 2006; 24: 3-9.
91. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al: Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13: 136-140. (Pubitemid 36790502)
92. Marrache F, Vullierme MP, Roy C, El Assoued Y, Couvelard A, O'Toole D, et al: Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 2007; 96: 49-55. (Pubitemid 46094638)
93. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71: 2624-2630. (Pubitemid 23100501)
94. Therasse E, Breittmayer F, Roche A, De-Baere T, Indushekar S, Ducreux M, et al: Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993; 189: 541-547. (Pubitemid 23321441)
95. Perry L, Stuart K, Stokes K, Clouse M: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111-1117. (Pubitemid 24382174)
96. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE: Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009; 72: 517-528.
97. O'Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003; 10: 463-468. (Pubitemid 38094883)
98. Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H: Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors -a retrospective single-center analysis. Digestion 2003; 68: 94-101. (Pubitemid 38056710)
99. 90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg 2008; 247: 1029-1035. (Pubitemid 351770424)
100. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90 Y microspheres: Early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279.
101. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113: 921.
102. Modlin IM, Pavel ME, Kidd M, Gustafsson B: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 2010; 31: 169-188.
103. Öberg K: Interferon in the management of neuroendocrine GEP tumors. Digestion 2000; 62(suppl 1):92-97. (Pubitemid 30665946)
104. Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T: Efficacy and tolerability of pegylated IFN-α in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006; 26: 8-13. (Pubitemid 43201732)
105. Jensen RT, Cadiot G, Brandi ML, et al: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
106. Kulke MH, Bergsland EK, Yao JC: Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360: 195-197.
107. Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG: Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010; 162: 1001-1008.
108. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al: Treatment with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
109. Ho KW, Wong CC, Balalla B, Diamond T: Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy. Clin Endocrinol (Oxf) 2006; 65: 410-411.
110. Chandra P, Yarandi SS, Khazai N, Jacobs S, Umpierrez GE: Management of intractable hypoglycemia with yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci 2010; 340: 414-417.
111. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al: Octreotide versus octreotide plus interferon in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771. (Pubitemid 41116728)
112. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al: International Lanreotide and Interferon Alfa Study Group: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors -the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696. (Pubitemid 46606312)
113. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, et al: Highdose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004; 151: 107-112. (Pubitemid 39117371)
114. Butturini G, Bettini R, Missiaglia E, et al: Predictive factors of efficacy of the somatostatin analogue octreotide as first-line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006; 13: 1213-1221. (Pubitemid 46212575)
115. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, et al: Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159: 475-482.
116. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, et al: Gastric endocrine tumors type I: Treatment with longacting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-342. (Pubitemid 351449751)
117. Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, et al: Fédération Francophone de Cancérologie Digestive (FFCD); Digestive Tumors Group of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC): Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon-α for advanced carcinoid tumors: FNCLCCFFCD 9710 Endocr Rel Cancer 2009; 16: 1351-1361.
118. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904. (Pubitemid 46223995)
119. Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F, et al: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009; 9: 388.
120. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, et al: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and highgrade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59: 637-642. (Pubitemid 46295128)
121. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, et al: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 2004; 40: 515-520. (Pubitemid 38220767)
122. Fjallskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK: Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 2008; 88: 53-58. (Pubitemid 352009119)
123. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-523.
124. Moertel CG, Hanley JA, Johnson LA: Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189-1194. (Pubitemid 11207582)
125. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al: Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010; 102: 1106-1112.
126. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
127. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-2991. (Pubitemid 46849574)
128. 6 -methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15: 338-345.
129. Moertel C, Kvols L, O'Connell M, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232.
130. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617-4622.
131. Pape U, Tiling N, Bartel C, Plöckinger U, Wiedenmann B: Oxaliplatin plus 5-fluorouracil/ folinic acid as palliative treatment for progressive malignant gastrointestinal neuroendocrine carcinomas. J Clin Oncol 2006; 24(suppl):14074.
132. Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K: Neuroendocrine tumors of the stomach: Chemotherapy with cisplatin plus irinotecan is effective for gastric poorlydifferentiated neuroendocrine carcinoma. Gastric Cancer 2011; 14: 161-165.
133. Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, Broelsch C: Treatment with 90 Y-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006; 140: 968-976.
134. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90 YDOTATOC. J Nucl Med 2002; 43: 610-616. (Pubitemid 34507110)
135. Kwekkeboom DJ, de Herder WW, Kam BL et al: Treatment with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2130.
136. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP: Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010; 40: 78-88.
137. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28: 1652-1659.
138. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009; 90: 220-226.
139. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010; 28 69-76.
140. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
141. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
142. Raymond E, Dahan L, Raoul J-L, Bang YJ, Borbath I, Lombard-Bohas C, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
143. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hoersch D, Winkler R, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378(9808):2005-2012.